CXCR3 expression on peripheral CD4+ T cells as a predictive marker of response to treatment in chronic hepatitis C

被引:13
作者
Perney, Pascal [2 ]
Turriere, Chrystell [3 ]
Portales, Pierre [4 ]
Rigole, Helene [3 ]
Psomas, Christina [4 ]
Blanc, Francois [3 ]
Clot, Jacques [4 ]
Corbeau, Pierre [1 ,4 ]
机构
[1] Hop Caremeau, UF Immunol, F-30029 Nimes, France
[2] Hop Caremeau, Serv Addictol, F-30029 Nimes, France
[3] Hop St Eloi, Serv Med Interne E, F-34295 Montpellier 5, France
[4] Hop St Eloi, Immunol Lab, F-34295 Montpellier 5, France
关键词
HCV; CCR5; Chemokine receptor; Interferon; Ribavirin; Aspartate aminotransferase; Liver fibrosis; HCV load; RECEPTOR; 5-DELTA-32/DELTA-32; GENOTYPE; SURFACE EXPRESSION; GENE-EXPRESSION; VIRUS-INFECTION; I-TAC; CHEMOKINE; FREQUENCY; CCR5; LYMPHOCYTES; BINDING;
D O I
10.1016/j.clim.2009.03.521
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
We monitored in fifty individuals with chronic hepatitis C (CHC) the expression of CCR5 and CXCR3, two chemokine receptors involved in the intra-hepatic recruitment of T cells, at the surface of circulating CD4(+) T cells. The percentage of CD4(+) T cells expressing CCR5 and/or CXCR3 was increased in patients. The increased percentage of CD4(+) CXCR3(+) T lymphocytes was linked to serum level of aspartate aminotransferase (AST) and to fibrosis METAVIR score. CD4(+) T cell surface CCR5 and CXCR3 densities increased after 6 months of treatment with pegylated interferon-alpha and ribavirin. The pre-therapeutic percentage of CD4(+) CXCR3(+) T cells was correlated with atanine aminotransferase serum level at 12 months, and viral load at 24 months after treatment initiation. Thus, in CHC we observed a high CXCR3 expression on peripheral blood CD4(+) T cells which correlates with AST serum level and liver fibrosis, and is predictive of the response to treatment. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 42 条
[1]
T helper, cytotoxic T lymphocyte, NK cell and NK-T cell subpopulations in patients with chronic hepatitis C [J].
Amaraa, R ;
Marecková, H ;
Urbánek, P ;
Fucíková, T .
FOLIA MICROBIOLOGICA, 2002, 47 (06) :717-722
[2]
Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells:: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins [J].
Apolinario, A ;
Majano, PL ;
Lorente, R ;
Núñez, O ;
Clemente, G ;
García-Monzón, C .
JOURNAL OF VIRAL HEPATITIS, 2005, 12 (01) :27-37
[3]
Apolinario A, 2002, AM J GASTROENTEROL, V97, P2861, DOI 10.1111/j.1572-0241.2002.07054.x
[4]
Bermejo M, 1998, EUR J IMMUNOL, V28, P3192
[5]
Kinetics of the immune response during HBV and HCV infection [J].
Bertoletti, A ;
Ferrari, C .
HEPATOLOGY, 2003, 38 (01) :4-13
[6]
Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy [J].
Blanco, J ;
Cabrera, C ;
Jou, A ;
Ruiz, L ;
Clotet, B ;
Esté, JA .
AIDS, 1999, 13 (05) :547-555
[7]
Liver-infiltrating lymphocytes in end-stage hepatitis C virus: Subsets, activation status, and chemokine receptor phenotypes [J].
Boisvert, J ;
Kunkel, EJ ;
Campbell, JJ ;
Keeffe, EB ;
Butcher, EC ;
Greenberg, HB .
JOURNAL OF HEPATOLOGY, 2003, 38 (01) :67-75
[8]
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s [J].
Bonecchi, R ;
Bianchi, G ;
Bordignon, PP ;
D'Ambrosio, D ;
Lang, R ;
Borsatti, A ;
Sozzani, S ;
Allavena, P ;
Gray, PA ;
Mantovani, A ;
Sinigaglia, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :129-134
[9]
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C [J].
Butera, D ;
Marukian, S ;
Iwamaye, AE ;
Hembrador, E ;
Chambers, TJ ;
Di Bisceglie, AM ;
Charles, ED ;
Talal, AH ;
Jacobson, IM ;
Rice, CM ;
Dustin, LB .
BLOOD, 2005, 106 (04) :1175-1182
[10]
A unique pattern of up- and down-regulation of chemokine receptor CXCR3 on inflammation-inducing Th1 cells [J].
Chen, J ;
Vistica, BP ;
Takase, H ;
Ham, DI ;
Fariss, RN ;
Wawrousek, EF ;
Chan, CC ;
DeMartino, JA ;
Farber, JM ;
Gery, I .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (10) :2885-2894